Get Sample Pages - GLP-1 Receptor Agonist Market Size & Growth Forecast by 2032

Global GLP-1 Receptor Agonist Market Research Report: Forecast (2026–2032)

Global GLP-1 Receptor Agonist Market - By Product Type (Semaglutide, Ozempic, Wegovy, Rybelsus, Others, Liraglutide, Victoza, Saxenda, Others, Exenatide, Dulaglutide, Other (tirzep......atide etc.), By Duration (Long-acting GLP-1 Receptor Agonists, Short-acting GLP-1 Receptor Agonists), By Application (Type-2 Diabetes Mellitus, Obesity & Weight Management, Cardiovascular, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and others Read more

Healthcare
Mar 2026
Pages 450
Report Format: PDF, Excel, PPT

Global GLP-1 Receptor Agonist Market Report Key Takeaways:

Market size was valued at around USD 52.39 billion in 2025 and is projected to grow from USD 63.2 billion in 2026 to USD 78.4 billion by 2032. The estimated CAGR from 2026 to 2032 is around 3.66%, indicating strong growth.
North America holds the largest market share of about 52.3% in the Global GLP-1 Receptor Agonist Market in 2026.
By Product Type, the semaglutide segment represented a significant share of about 35% in the Global GLP-1 Receptor Agonist Market in 2026.
By Application, the obesity and weight management segment presented a significant share in the Global GLP-1 Receptor Agonist Market in 2026.
Leading GLP-1 Receptor Agonist Companies in the Global Market are Novo Nordisk A/S, Eli Lilly & Company, AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Sanofi, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Amgen Inc., Hanmi Pharmaceutical Co., Ltd., Amneal Pharmaceuticals, Inc., Biocon Ltd., Glenmark Pharmaceuticals Ltd., Takeda Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd., and Others.

Global GLP-1 Receptor Agonist Market Size: Forecast (2026-2032)

The Global GLP-1 Receptor Agonist Market size was valued at around USD 52.39 billion in 2025 and is projected to grow from USD 63.2 billion in 2026 to USD 78.4 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 3.66% during the forecast period, i.e., 2026-32.

Global GLP-1 Receptor Agonist Market Outlook:

The Global GLP-1 Receptor Agonist Market is entering a strong expansion phase as healthcare systems worldwide prioritize advanced metabolic therapies. For instance, in Japan, a steady rise in metabolic syndrome cases, which ranges between 25-30% requiring lifestyle or pharmacological intervention by 2023, illustrates the growing therapeutic need in East Asia. Likewise, Brazil’s Ministry of Health reported in 2024 that nearly 60% of adults were overweight, reinforcing wider momentum for modern hormonal therapies across emerging economies.

This expanding therapeutic landscape is also influenced by evolving treatment pathways in major global markets, including the United States, China, India, and Germany, which are strengthening obesity- and diabetes-care frameworks. Additionally, the European Commission advanced chronic-disease initiatives in 2024, including digital metabolic-care tools that integrate GLP-1 adherence, reflecting a shift toward long-term management.

In Addition, the rising investments in increasing the production capacities to produce GLP-1 receptor agonist worldwide, contributing to the market growth. For instance, in July 2024, CordenPharma announced a USD 980 million expansion to increase production of GLP-1 peptides in the US and Europe. This investment aims to meet growing global demand for GLP-1 drugs and reduce future supply shortages.

Similarly, Australia’s Therapeutic Goods Administration (TGA) updated prescribing guidelines in 2024 to prioritize high-risk patients as GLP-1 demand increased across both metropolitan and regional health networks, creating a broader global foundation for sustained GLP-1 adoption without relying on repeated data points.

Collectively, these trends signal an increasingly integrated global response, positioning GLP-1 therapies as core components of metabolic health through the coming decade.

Global GLP-1 Receptor Agonist Market Recent Developments:

2025: Eli Lilly's once-daily oral GLP-1 agonist Orforglipron completed Phase III trials, delivering meaningful weight loss and strong blood-glucose (A1C) reduction.
2025: Biocon strengthened its GLP-1 presence with two key milestones. In February 2025, it launched its liraglutide product in the UK for diabetes and obesity treatment. Likewise, in June 2025, Biocon received regulatory approval in India for its injectable liraglutide in pre-filled pen and cartridge formats, expanding market access.
2025: Novo Nordisk received U.S. FDA approval for its once-daily oral semaglutide (Wegovy) tablet, becoming the first oral GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight conditions. The pill formulation provides a convenient alternative to injectable therapies and was commercially launched in the United States in early 2026, expanding treatment accessibility in the rapidly growing obesity and metabolic disease therapeutics market.

Global GLP-1 Receptor Agonist Market Scope:

Category	Segments
By Product Type	Semaglutide, Ozempic, Wegovy, Rybelsus, Others, Liraglutide, Victoza, Saxenda, Others, Exenatide, Dulaglutide, Other (tirzepatide etc.),
By Duration	Long-acting GLP-1 Receptor Agonists, Short-acting GLP-1 Receptor Agonists),
By Application	Type-2 Diabetes Mellitus, Obesity & Weight Management, Cardiovascular, Others),
By Route of Administration	Oral, Injectable, Others),
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and others

Global GLP-1 Receptor Agonist Market Drivers:

Increasing Cases of Obesity & Overweight Driving Market Demand

Global obesity and overweight trends are accelerating the demand for advanced therapies. According to the World Health Organization (WHO), in 2022, roughly 1 in 8 people worldwide lived with obesity, with some 890 million adults classified as obese and nearly 2.5 billion adults overweight. As obesity becomes more common globally, the potential patient pool for GLP-1 receptor agonists expands significantly.

Many high-income and middle-income countries share this burden. For instance, among OECD member states, recent data (2023) show that over 54% of adults are overweight or obese, and 18% are obese, underscoring widespread metabolic stress in developed healthcare systems.

Moreover, the higher obesity prevalence is projected to increase up to 1.13 billion by the end of 2030, illustrating that GLP-1 demand is not limited to large economies but includes diverse global regions.

In response, pharmaceutical companies are ramping up capacity and regulatory efforts to meet global demand. For instance, global expansion of GLP-1 production facilities, broader regulatory approvals across multiple continents, and increasing inclusion of GLP-1 in national health strategies reflect a coordinated move to address the worldwide obesity and metabolic-disease crisis. As long as overweight and obesity rates continue rising, GLP-1 therapies are likely to remain front-line pharmacological tools.

Market Segmentation
Introduction
1. Market Definition
2. Research Process
3. Assumption
Executive Summary
Global GLP-1 Receptor Agonist Market Trends & Development
Global GLP-1 Receptor Agonist Market Dynamics
1. Growth Drivers
2. Challenges
Global GLP-1 Receptor Agonist Market Hotspot & Opportunities
Global GLP-1 Receptor Agonist Market Regulation & Policy
Global GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product Type
    1. Semaglutide- Market Size & Forecast 2022-2032, USD Million
      1. Ozempic- Market Size & Forecast 2022-2032, USD Million
      2. Wegovy- Market Size & Forecast 2022-2032, USD Million
      3. Rybelsus- Market Size & Forecast 2022-2032, USD Million
      4. Others- Market Size & Forecast 2022-2032, USD Million
    2. Liraglutide- Market Size & Forecast 2022-2032, USD Million
      1. Victoza- Market Size & Forecast 2022-2032, USD Million
      2. Saxenda- Market Size & Forecast 2022-2032, USD Million
      3. Others- Market Size & Forecast 2022-2032, USD Million
    3. Exenatide- Market Size & Forecast 2022-2032, USD Million
    4. Dulaglutide- Market Size & Forecast 2022-2032, USD Million
    5. Other (tirzepatide etc.) - Market Size & Forecast 2022-2032, USD Million
  2. By Duration
    1. Long-acting GLP-1 Receptor Agonists- Market Size & Forecast 2022-2032, USD Million
    2. Short-acting GLP-1 Receptor Agonists- Market Size & Forecast 2022-2032, USD Million
  3. By Application
    1. Type-2 Diabetes Mellitus- Market Size & Forecast 2022-2032, USD Million
    2. Obesity & Weight Management- Market Size & Forecast 2022-2032, USD Million
    3. Cardiovascular- Market Size & Forecast 2022-2032, USD Million
    4. Others- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration
    1. Oral- Market Size & Forecast 2022-2032, USD Million
    2. Injectable- Market Size & Forecast 2022-2032, USD Million
    3. Others- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel
    1. Hospital Pharmacies- Market Size & Forecast 2022-2032, USD Million
    2. Retail Pharmacies- Market Size & Forecast 2022-2032, USD Million
    3. Online Pharmacies- Market Size & Forecast 2022-2032, USD Million
  6. By Region
    1. North America
    2. South America
    3. Europe
    4. The Middle East & Africa
    5. Asia-Pacific
  7. By Company
    1. Competition Characteristics
    2. Revenue Shares
North America GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product- Market Size & Forecast 2022-2032, USD Million
  2. By Duration- Market Size & Forecast 2022-2032, USD Million
  3. By Application- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
  6. By Country
    1. The US
    2. Canada
    3. Mexico
3. The US GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
4. Canada GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
5. Mexico GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
South America GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product- Market Size & Forecast 2022-2032, USD Million
  2. By Duration- Market Size & Forecast 2022-2032, USD Million
  3. By Application- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
  6. By Country
    1. Brazil
    2. Argentina
    3. Rest of South America
3. Brazil GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
4. Argentina GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
Europe GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product- Market Size & Forecast 2022-2032, USD Million
  2. By Duration- Market Size & Forecast 2022-2032, USD Million
  3. By Application- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
  6. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
3. The UK GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
4. Germany GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
5. France GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
6. Italy GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
7. Spain GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
The Middle East & Africa GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product- Market Size & Forecast 2022-2032, USD Million
  2. By Duration- Market Size & Forecast 2022-2032, USD Million
  3. By Application- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
  6. By Country
    1. Saudi Arabia
    2. The UAE
    3. South Africa
    4. Rest of the Middle East & Africa
3. Saudi Arabia GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
4. The UAE GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
5. South Africa GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
Asia-Pacific GLP-1 Receptor Agonist Market Outlook, 2022-2032F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Product- Market Size & Forecast 2022-2032, USD Million
  2. By Duration- Market Size & Forecast 2022-2032, USD Million
  3. By Application- Market Size & Forecast 2022-2032, USD Million
  4. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  5. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
  6. By Country
    1. China
    2. Japan
    3. South Korea
    4. India
    5. Australia
    6. Rest of Asia-Pacific
3. China GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
4. Japan GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
5. South Korea GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
6. India GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
7. Australia GLP-1 Receptor Agonist Market Outlook, 2022-2032F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Size & Analysis
    1. By Product- Market Size & Forecast 2022-2032, USD Million
    2. By Duration- Market Size & Forecast 2022-2032, USD Million
    3. By Application- Market Size & Forecast 2022-2032, USD Million
Global GLP-1 Receptor Agonist Market Key Strategic Imperatives for Success & Growth
Competitive Outlook
1. Company Profiles
  1. Novo Nordisk A/S
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  2. Eli Lilly & Company
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  3. AstraZeneca plc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  4. Merck & Co., Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  5. Pfizer Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Sanofi
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  7. GlaxoSmithKline plc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  8. Boehringer Ingelheim International GmbH
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Amgen Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  10. Hanmi Pharmaceutical Co., Ltd.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  11. Amneal Pharmaceuticals, Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  12. Biocon Ltd.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  13. Glenmark Pharmaceuticals Ltd.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  14. Takeda Pharmaceutical Co. Ltd
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  15. Sun Pharmaceutical Industries Ltd.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  16. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO GET THE FREE SAMPLE PAGES

Name *

Email ID *

Country *